NCT04882683 is a NA clinical trial of Prednisone in Ulcerative Colitis, sponsored by Shandong Qilu Stem Cells Engineering Co., Ltd..

Who is sponsoring NCT04882683?

NCT04882683 is sponsored by Shandong Qilu Stem Cells Engineering Co., Ltd..

What drugs are being tested in NCT04882683?

Interventions in NCT04882683: Prednisone, Azathioprine, Adalimumab, umbilical cord blood mononuclear cells.

What condition does NCT04882683 study?

NCT04882683 studies Ulcerative Colitis.

Is NCT04882683 still recruiting?

NCT04882683 is currently status unknown. Last updated 12 May 2021.

Last reviewed 2021-05-12 · How we verify

NCT04882683

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis

Status unknown NA Last updated 12 May 2021

What this trial tests

NA trial testing Prednisone in Ulcerative Colitis in 50 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
1 June 2022

31 December 2022

Quick facts

Lead sponsor	Shandong Qilu Stem Cells Engineering Co., Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 June 2021
Primary completion	1 June 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

Prednisone (prednisone) — full drug profile →
Azathioprine (AZATHIOPRINE) — full drug profile →
Adalimumab (ADALIMUMAB) — full drug profile →
umbilical cord blood mononuclear cells — full drug profile →

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →

Sponsor

Shandong Qilu Stem Cells Engineering Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fresh Umbilical Cord Blood-A Source of Multipotent Stem Cells, Collection, Banking, Cryopreservation, and Ethical Concerns.
Devi S, Bongale AM, Tefera MA, Dixit P, et al · · 2023 · cited 17× · PMID 37763198 · DOI 10.3390/life13091794

Verify or expand the search:

Other trials of Prednisone

Trials testing the same drug.

NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Shandong Qilu Stem Cells Engineering Co., Ltd. trials

Trials by the same sponsor.

NCT07201233 — Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression . · NA · not yet recruiting
NCT06427642 — Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases · NA · recruiting
NCT03529136 — Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04882683 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong Qilu Stem Cells Engineering Co., Ltd.
Last refreshed: 12 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04882683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing